- NAMSA 유럽 심혈관 치료분야 전문 CRO, AKRN 인수합병
- 등록일2022-03-22
2022년 3월21일 글로벌 MedTech CRO의 선두주자인 NAMSA가 의료기기 개발의 전주기 솔루션을 제공하기 위해 유럽 의료기기 CRO인 AKRN Scientific Consulting의 인수계획을 발표했습니다.
NAMSA는 AKRN 인수합병을 통해 심혈관 치료분야 전문 역량을 향상시킬 수 있게 되었으며 아시아, 유럽, 북미, 남미에 걸쳐 19 개의 도시에서 서비스를 제공할 수 있게 될 예정입니다.
자세한 사항은 NAMSA 홈페이지에서 확인하실 수 있습니다.
-------------------------------
TOLEDO, OHIO and MADRID, SPAIN – BUSINESSWIRE—MARCH 21, 2022
NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its intent to acquire AKRN Scientific Consulting, a prominent European Medical Device CRO based in Madrid, Spain.
ÅKRN, founded in 2018, focuses on providing exceptional clinical and regulatory services to the medical device and diagnostic industries in Europe. Grounded in medicine and science, the organization assists Sponsors move MedTech products from medical discovery into clinical development, commercialization and Post-Market Follow-Up. Known for their expertise in Cardiovascular research, ÅKRN’s Team of Clinical Scientists and Project Managers serve as trusted Client Advisors throughout the complete clinical development process via diligent planning and superior execution.
“We are thrilled to welcome ÅKRN to NAMSA,” said Dr. Christophe Berthoux, CEO of NAMSA. “The organization is well-respected for their proficiency in European medical device regulations and providing exceptional clinical support to MedTech Sponsors. Adding them to our team will expand our depth of expertise, enabling us to meet the growing demand for safe, efficient clinical development and commercialization of life-changing medical products,” Dr. Berthoux concluded.
The acquisition of ÅKRN increases NAMSA’s global scale, now serving MedTech Clients across 19 locations throughout APAC, Europe, North America and South America.
